Subjects who undergo gastrointestinal diagnostic endoscopy or gastrointestinal endoscopic polypectomy
Conditions
Interventions
investigational material(s)
Generic name etc : Propofol(ICI35,868)
INN of investigational material : Propofol
Therapeutic category code : 111 General anesthetics
Dosage and Administration for Investig
Sponsors
AstraZeneca
Johnson & Johnson
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Provision of written informed consent prior to any study-related procedures/examinations 2. Aged 20 years and older 3. Subjects who are planned to undergo a non-emergent EGD or colonoscopy, including gastrointestinal endoscopic polypectomy that shall be completed within 1 hour (excluding the endoscopic submucosal dissection and ultrasonic endoscope, pernasal endoscope, etc.).
Exclusion criteria
Exclusion criteria: 1. involvement in the planning and/or conduct of the study (applies to both sponsor's employees and/or staffs at the study site) 2. Subjects who underwent a endoscopic procedure under ICI35,868 (propofol) administration within 1 year. 3. Participation in another clinical study with an investigational product within 4 weeks prior to randomisation. 4. Baseline (Visit 1) of blood oxygen saturation (SpO2)<90% (room air) 5. ASA III, IV, V and VI ; Subject with serious disease of cardiovascular, respiratory, renal, liver, pancreatic or endocrine function.
Outcome results
None listed